09:17 EDT Targacept to further reduce workforce after drug misses endpoint in trial
The flap over Apple’s corporate tax strategy might sound like a snoozer, until you consider who makes up the difference …
Targacept to further reduce workforce after drug misses endpoint in trial
Theflyonthewall.com – Mon, Sep 17, 2012 9:17 AM EDTRELATED QUOTES
| Symbol | Price | Change |
|---|---|---|
| TRGT | 5.58 | 0.04 |
Related Content
- Halozyme rises on prostate cancer drug study
- Peregrine rises on agreement for late-stage study
- ESPN cutting workforce, 'smartly managing costs'
- Oncothyreon slumps on new cancer drug data
- France: Drugmaker on trial, suspected in deaths
- FDA has safety concerns on Merck insomnia drug
- FDA approves genetic test for lung cancer drug
- FDA approves radiation-based prostate cancer drug
- Targacept gets a show of support
- The real reason Americans are missing out on life-saving drugs
- Vivus seeks fat-drug partner
- Gilead Sciences climbs to all-time highs
- FDA approves Merck combination cholesterol pill
- Unusual trade is bullish on Targacept
Recent Quotes Symbol Price Change % Chg Chart Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.Recent Quotes News
- Sign-in to view quotes in your portfolios.
Here’s Who Pays the Bill for Apple’s Tax AvoidanceThe Exchange- Kudlow: Bernanke Was Right About InflationDaily Ticker Videos
Trading Center
Today on Yahoo!
1 - 6 of 48
Yahoo! Finance on Facebook
@YahooFinance on Twitter
POLL
Apple CEO Tim Cook will face Congress today over corporate taxes. Should companies pay more?
Loading...